Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Invir.IO

Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies

20190502 – TG-AZ agreement – ENG

Published 2 May 2019
Categorized as 2019, Invir.IO, Press release

Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors

20190326 PR BioInvent extension CDR US

Published 26 March 2019
Categorized as 2019, Invir.IO, Press release

Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment

Jean-Baptiste Marchand et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation Collaboration between Transgene – BioInvent International A.B, Sweden

Published 7 November 2018
Categorized as -others, 2018, Invir.IO, Publication, TG6002

Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference

20181107 SITC Poster EN

Published 7 November 2018
Categorized as 2018, Invir.IO, Myvac, Press release

Transgene and BioInvent present positive data at the SITC, supporting the co-development of a next-generation oncolytic virus encoding for an anti-CTLA-4 antibody

20181107 SITC Joint BioInvent Transgene EN

Published 7 November 2018
Categorized as 2018, Invir.IO, Press release

Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference

20181001 SITC Poster VEN

Published 2 October 2018
Categorized as 2018, Invir.IO, Myvac, Press release

BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors

BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors

Published 6 December 2017
Categorized as 2017, Invir.IO, Press release

Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors

20171002-PR-TG-Randox-final

Published 2 October 2017
Categorized as 2017, Invir.IO, Press release

Transgene Launches Invir.IO™, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses

20170905 Invirio PR US

Published 21 September 2017
Categorized as 2017, Invir.IO, Press release

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition

Patricia Kleinpeter, et al.OncoImmunology, October 2016 – Download the articlePublication

Published 28 October 2016
Categorized as -others, 2017, Invir.IO, Publication

Posts pagination

Newer posts Page 1 … Page 5 Page 6 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu